{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:04:56Z","timestamp":1793815496921,"version":"4.6.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"DOI":"10.1186\/s12987-025-00737-7","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:20:04Z","timestamp":1764253204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Transferrin receptor-binding blood-brain barrier shuttle enhances brain delivery and plaque-clearing efficacy of a therapeutic anti-A\u03b2 antibody"],"prefix":"10.1186","volume":"22","author":[{"given":"Marta Ramos","family":"Vega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik H.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Stampe","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdoxia","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Wichern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiken S\u00f8ndergaard","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Lercke","family":"Skytte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper Graversen","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Sotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vergo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hecksher-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"737_CR1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"C van Dyck","year":"2023","unstructured":"van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:142\u20133.","journal-title":"N Engl J Med"},{"key":"737_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"737_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks JD, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"737_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"737_CR5","doi-asserted-by":"crossref","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8:217.","DOI":"10.1038\/s41392-023-01481-w"},{"key":"737_CR6","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","volume":"91","author":"JF Poduslo","year":"1994","unstructured":"Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc Natl Acad Sci U S A. 1994;91:5705\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"737_CR7","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","volume":"33","author":"I St-Amour","year":"2013","unstructured":"St-Amour I, Par\u00e9 I, Alata W, Coulombe K, Ringuette-Goulet C, Drouin-Ouellet J, et al. Brain bioavailability of human intravenous Immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab. 2013;33:1983\u201392.","journal-title":"J Cereb Blood Flow Metab"},{"key":"737_CR8","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","volume":"24","author":"WM Pardridge","year":"2007","unstructured":"Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24:1733\u201344.","journal-title":"Pharm Res"},{"key":"737_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph13110394","volume":"13","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM. Treatment of alzheimer\u2019s disease and Blood-Brain barrier drug delivery. Pharmaceuticals (Basel). 2020;13:1\u201325.","journal-title":"Pharmaceuticals (Basel)"},{"key":"737_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","volume":"120","author":"PO Freskg\u00e5rd","year":"2017","unstructured":"Freskg\u00e5rd PO, Urich E. Antibody therapies in CNS diseases. Neuropharmacology. 2017;120:38\u201355.","journal-title":"Neuropharmacology"},{"key":"737_CR11","doi-asserted-by":"crossref","unstructured":"Aziz AA, Amtul Z. Developing Trojan horses to induce, diagnose and suppress alzheimer\u2019s pathology. Pharmacol Res. 2019;149:104471.","DOI":"10.1016\/j.phrs.2019.104471"},{"key":"737_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/312162a0","volume":"312","author":"WA Jefferies","year":"1984","unstructured":"Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312:162\u20133.","journal-title":"Nature"},{"key":"737_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1006948027674","volume":"20","author":"T Moos","year":"2000","unstructured":"Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol. 2000;20:77\u201395.","journal-title":"Cell Mol Neurobiol"},{"key":"737_CR14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/0026-0495(87)90099-0","volume":"36","author":"WM Pardridge","year":"1987","unstructured":"Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier transferrin receptor. Metabolism. 1987;36:892\u20135.","journal-title":"Metabolism"},{"key":"737_CR15","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1073\/pnas.83.17.6445","volume":"83","author":"RS Ajioka","year":"1986","unstructured":"Ajioka RS, Kaplan J. Intracellular pools of transferrin receptors result from constitutive internalization of unoccupied receptors. Proc Natl Acad Sci U S A. 1986;83:6445\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"737_CR16","doi-asserted-by":"crossref","unstructured":"Pizzo ME, Plowey ED, Khoury N, Kwan W, Abettan J, DeVos SL, et al. Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. Science. 2025;389.","DOI":"10.1126\/science.ads3204"},{"key":"737_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","volume":"22","author":"F Weber","year":"2018","unstructured":"Weber F, Bohrmann B, Niewoehner J, Fischer JAA, Rueger P, Tiefenthaler G, et al. Brain shuttle antibody for alzheimer\u2019s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Rep. 2018;22:149\u201362.","journal-title":"Cell Rep"},{"key":"737_CR18","doi-asserted-by":"crossref","unstructured":"Grimm HP, Schumacher V, Sch\u00e4fer M, Imhof-Jung S, Freskg\u00e5rd PO, Brady K, et al. Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs. 2023;15:2261509.","DOI":"10.1080\/19420862.2023.2261509"},{"key":"737_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49\u201360.","journal-title":"Neuron"},{"key":"737_CR20","doi-asserted-by":"crossref","unstructured":"Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6:261ra154.","DOI":"10.1126\/scitranslmed.3009835"},{"key":"737_CR21","doi-asserted-by":"crossref","unstructured":"Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.","DOI":"10.1126\/scitranslmed.3002230"},{"key":"737_CR22","doi-asserted-by":"crossref","unstructured":"Gustavsson T, Metzendorf NG, Wik E, Roshanbin S, Julku U, Chourlia A, et al. Long-term effects of immunotherapy with a brain penetrating A\u03b2 antibody in a mouse model of alzheimer\u2019s disease. Alzheimers Res Ther. 2023;15:90.","DOI":"10.1186\/s13195-023-01236-3"},{"key":"737_CR23","doi-asserted-by":"crossref","unstructured":"Syv\u00e4nen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, S\u00f6derberg L, et al. Efficient clearance of A\u03b2 protofibrils in A\u03b2PP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimers Res Ther. 2018;10:49.","DOI":"10.1186\/s13195-018-0377-8"},{"key":"737_CR24","doi-asserted-by":"crossref","unstructured":"Gustavsson T, Syv\u00e4nen S, O\u2019Callaghan P, Sehlin D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-\u03b2 antibody in a mouse model of alzheimer\u2019s disease. Transl Neurodegener. 2020;9:37.","DOI":"10.1186\/s40035-020-00214-1"},{"key":"737_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-neuro-070918-050357","volume":"42","author":"EMC Hillman","year":"2019","unstructured":"Hillman EMC, Voleti V, Li W, Yu H. Light-Sheet microscopy in neuroscience. Annu Rev Neurosci. 2019;42:295\u2013313.","journal-title":"Annu Rev Neurosci"},{"key":"737_CR26","doi-asserted-by":"crossref","unstructured":"Ueda HR, Ert\u00fcrk A, Chung K, Gradinaru V, Ch\u00e9dotal A, Tomancak P, et al. Tissue clearing and its applications in neuroscience. Nat Rev Neurosci. 2020: [Epub ahead of print].","DOI":"10.1038\/s41583-019-0250-1"},{"key":"737_CR27","doi-asserted-by":"crossref","unstructured":"Roostalu U, Hansen HH, Hecksher-S\u00f8rensen J. 3D light-sheet fluorescence microscopy in preclinical and clinical drug discovery. Drug Discov Today. 2024;29:104196.","DOI":"10.1016\/j.drudis.2024.104196"},{"key":"737_CR28","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.4103\/1673-5374.284983","volume":"15","author":"HH Hansen","year":"2020","unstructured":"Hansen HH, Roostalu U, Hecksher-S\u00f8rensen J. Whole-brain three-dimensional imaging for quantification of drug targets and treatment effects in mouse models of neurodegenerative diseases. Neural Regen Res. 2020;15:2255\u20137.","journal-title":"Neural Regen Res"},{"key":"737_CR29","doi-asserted-by":"crossref","unstructured":"Gail Canter R, Huang WC, Choi H, Wang J, Ashley Watson L, Yao CG, et al. 3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice. Commun Biol. 2019;2:360.","DOI":"10.1038\/s42003-019-0599-8"},{"key":"737_CR30","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1002\/cne.24555","volume":"527","author":"JD Whitesell","year":"2019","unstructured":"Whitesell JD, Buckley AR, Knox JE, Kuan L, Graddis N, Pelos A, et al. Whole brain imaging reveals distinct Spatial patterns of amyloid beta deposition in three mouse models of alzheimer\u2019s disease. J Comp Neurol. 2019;527:2122\u201345.","journal-title":"J Comp Neurol"},{"key":"737_CR31","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.celrep.2016.06.060","volume":"16","author":"T Liebmann","year":"2016","unstructured":"Liebmann T, Renier N, Bettayeb K, Greengard P, Tessier-Lavigne M, Flajolet M. Three-Dimensional study of alzheimer\u2019s disease hallmarks using the iDISCO clearing method. Cell Rep. 2016;16:1138\u201352.","journal-title":"Cell Rep"},{"key":"737_CR32","doi-asserted-by":"crossref","unstructured":"Kirschenbaum D, Dadgar-Kiani E, Catto F, Voigt FF, Trevisan C, Bichsel O, et al. Whole-brain microscopy reveals distinct temporal and spatial efficacy of anti-A\u03b2 therapies. EMBO Mol Med. 2023;15:e16789.","DOI":"10.15252\/emmm.202216789"},{"key":"737_CR33","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","volume":"16","author":"N Khoury","year":"2025","unstructured":"Khoury N, Pizzo ME, Discenza CB, Joy D, Tatarakis D, Todorov I, et al. Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution compared to standard antibodies. Nat Commun. 2025;16:1822.","journal-title":"Nat Commun"},{"key":"737_CR34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/bit.22135","volume":"102","author":"RJ Boado","year":"2009","unstructured":"Boado RJ, Zhang Y, Wang Y, Pardridge WM. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng. 2009;102:1251\u20138.","journal-title":"Biotechnol Bioeng"},{"key":"737_CR35","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s00259-023-06109-3","volume":"50","author":"N Stergiou","year":"2023","unstructured":"Stergiou N, Wuensche TE, Schreurs M, Mes I, Verlaan M, Kooijman EJM, et al. Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-\u00df monoclonal antibody. Eur J Nucl Med Mol Imaging. 2023;50:1306\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"737_CR36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. Abeta42-driven cerebral amyloidosis in Transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940\u20136.","journal-title":"EMBO Rep"},{"key":"737_CR37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2014.10.010","volume":"159","author":"N Renier","year":"2014","unstructured":"Renier N, Wu Z, Simon DJ, Yang J, Ariel P, Tessier-Lavigne M. iDISCO: a simple, rapid method to Immunolabel large tissue samples for volume imaging. Cell. 2014;159:896\u2013910.","journal-title":"Cell"},{"key":"737_CR38","doi-asserted-by":"crossref","unstructured":"Perens J, Salinas CG, Skytte JL, Roostalu U, Dahl AB, Dyrby TB et al. An optimized mouse brain atlas for automated mapping and quantification of neuronal activity using iDISCO+ and light sheet fluorescence microscopy. Neuroinformatics. 2021;19:433\u201346.","DOI":"10.1007\/s12021-020-09490-8"},{"key":"737_CR39","doi-asserted-by":"crossref","unstructured":"Oh SW, Harris JA, Ng L, Winslow B, Cain N, Mihalas S et al. A mesoscale connectome of the mouse brain. Nature. 2014;508:207\u201314.","DOI":"10.1038\/nature13186"},{"key":"737_CR40","doi-asserted-by":"crossref","unstructured":"Klein S, Staring M, Murphy K, Viergever MA, Pluim JPW. elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging. 2010;29:196\u2013205.","DOI":"10.1109\/TMI.2009.2035616"},{"key":"737_CR41","doi-asserted-by":"crossref","unstructured":"Renier N, Adams EL, Kirst C, Wu Z, Azevedo R, Kohl J et al. mapping of brain activity by automated volume analysis of Immediate early genes. Cell. 2016;165:1789\u20131802.","DOI":"10.1016\/j.cell.2016.05.007"},{"key":"737_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JAD-200715","volume":"79","author":"J Bastrup","year":"2021","unstructured":"Bastrup J, Hansen KH, Poulsen TBG, Kastaniegaard K, Asuni AA, Christensen S, et al. Anti-A\u03b2 antibody aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a Transgenic mouse model of alzheimer\u2019s disease. J Alzheimers Dis. 2021;79:249\u201365.","journal-title":"J Alzheimers Dis"},{"key":"737_CR43","doi-asserted-by":"crossref","unstructured":"Wood JI, Dulewicz M, Ge J, Stringer K, Szadziewska A, Desai S, et al. Isotope Encoded chemical Imaging Identifies Amyloid Plaque Age Dependent Structural Maturation, Synaptic Loss, and Increased Toxicity. Nat Commun. 2025;16:8170.","DOI":"10.1038\/s41467-025-63328-y"},{"key":"737_CR44","doi-asserted-by":"crossref","unstructured":"Michno W, Stringer KM, Enzlein T, Passarelli MK, Escrig S, Vitanova K, et al. Following Spatial A\u03b2 aggregation dynamics in evolving alzheimer\u2019s disease pathology by imaging stable isotope labeling kinetics. Sci Adv. 2021;7:eabg4855.","DOI":"10.1126\/sciadv.abg4855"},{"key":"737_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0022-510X(90)90183-N","volume":"98","author":"B Giometto","year":"1990","unstructured":"Giometto B, Bozza F, Argentiero V, Gallo P, Pagni S, Piccinno MG, et al. Transferrin receptors in rat central nervous system. An immunocytochemical study. J Neurol Sci. 1990;98:81\u201390.","journal-title":"J Neurol Sci"},{"key":"737_CR46","doi-asserted-by":"crossref","unstructured":"Maktabi MA, Heistad DD, Faraci FM. Effects of angiotensin II on blood flow to choroid plexus. Am J Physiol. 1990;258:H414-8.","DOI":"10.1152\/ajpheart.1990.258.2.H414"},{"key":"737_CR47","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0165-5728(01)00242-9","volume":"114","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol. 2001;114:168\u201372.","journal-title":"J Neuroimmunol"},{"key":"737_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.brainres.2013.08.035","volume":"1534","author":"PR Cooper","year":"2013","unstructured":"Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson L, Li Q, et al. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res. 2013;1534:13\u201321.","journal-title":"Brain Res"},{"key":"737_CR49","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1113\/JP275105","volume":"596","author":"ME Pizzo","year":"2018","unstructured":"Pizzo ME, Wolak DJ, Kumar NN, Brunette E, Brunnquell CL, Hannocks MJ, et al. Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. J Physiol. 2018;596:445\u201375.","journal-title":"J Physiol"},{"key":"737_CR50","doi-asserted-by":"crossref","unstructured":"Baniel CC, Sumiec EG, Hank JA, Bates AM, Erbe AK, Pieper AA, et al. Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model. J Immunother Cancer. 2020;8:e001262.","DOI":"10.1136\/jitc-2020-001262"},{"key":"737_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/1721727X1401200310","volume":"12","author":"I F\u00fclber","year":"2014","unstructured":"F\u00fclber I, Bacher M, Dodel R, R\u00f6skam S. Evaluating the murine Anti-Human antibody response and assessment of general activity and cognition after treatment with human intravenous Immunoglobulins in healthy adult C57\/B6J mice. Eur J Inflamm. 2014;12:489\u201397.","journal-title":"Eur J Inflamm"},{"key":"737_CR52","doi-asserted-by":"publisher","first-page":"13542","DOI":"10.1523\/JNEUROSCI.4686-08.2008","volume":"28","author":"BH Han","year":"2008","unstructured":"Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, et al. Cerebrovascular dysfunction in amyloid precursor protein Transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase Inhibition. J Neurosci. 2008;28:13542\u201350.","journal-title":"J Neurosci"},{"key":"737_CR53","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/nm.3734","volume":"20","author":"FC Maier","year":"2014","unstructured":"Maier FC, Wehrl HF, Schmid AM, Mannheim JG, Wiehr S, Lerdkrai C, et al. Longitudinal PET-MRI reveals \u03b2-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat Med. 2014;20:1485\u201392.","journal-title":"Nat Med"},{"key":"737_CR54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","volume":"88","author":"N Bien-Ly","year":"2015","unstructured":"Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, et al. Lack of widespread BBB disruption in alzheimer\u2019s disease models: focus on therapeutic antibodies. Neuron. 2015;88:289\u201397.","journal-title":"Neuron"},{"key":"737_CR55","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1006\/nbdi.2001.0402","volume":"8","author":"JF Poduslo","year":"2001","unstructured":"Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double Transgenic mouse model of alzheimer\u2019s disease. Neurobiol Dis. 2001;8:555\u201367.","journal-title":"Neurobiol Dis"},{"key":"737_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","volume":"143","author":"S Gustafsson","year":"2018","unstructured":"Gustafsson S, Gustavsson T, Roshanbin S, Hultqvist G, Hammarlund-Udenaes M, Sehlin D, et al. Blood-brain barrier integrity in a mouse model of alzheimer\u2019s disease with or without acute 3D6 immunotherapy. Neuropharmacology. 2018;143:1\u20139.","journal-title":"Neuropharmacology"},{"key":"737_CR57","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/brain\/awab387","volume":"145","author":"M Ali","year":"2022","unstructured":"Ali M, Falkenhain K, Njiru BN, Murtaza-Ali M, Ruiz-Uribe NE, Haft-Javaherian M, et al. VEGF signalling causes stalls in brain capillaries and reduces cerebral blood flow in alzheimer\u2019s mice. Brain. 2022;145:1449\u201363.","journal-title":"Brain"},{"key":"737_CR58","doi-asserted-by":"crossref","unstructured":"Leinenga G, Koh WK, G\u00f6tz J. A comparative study of the effects of aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of alzheimer disease. Alzheimers Res Ther. 2021;13:76.","DOI":"10.1186\/s13195-021-00809-4"},{"key":"737_CR59","doi-asserted-by":"crossref","unstructured":"Kong C, Yang EJ, Shin J, Park J, Kim SH, Park SW, et al. Enhanced delivery of a low dose of aducanumab via FUS in 5\u00d7FAD mice, an AD model. Transl Neurodegener. 2022;11:57.","DOI":"10.1186\/s40035-022-00333-x"},{"key":"737_CR60","doi-asserted-by":"crossref","unstructured":"Cadiz MP, Gibson KA, Todd KT, Nascari DG, Massa N, Lilley MT, et al. Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations. J Exp Med. 2024;221:e20231363.","DOI":"10.1084\/jem.20231363"},{"key":"737_CR61","doi-asserted-by":"crossref","unstructured":"Willuweit A, Velden J, Godemann R, Manook A, Jetzek F, Tintrup H, et al. Early-onset and robust amyloid pathology in a new homozygous mouse model of alzheimer\u2019s disease. PLoS ONE. 2009;4:e7931.","DOI":"10.1371\/journal.pone.0007931"},{"key":"737_CR62","unstructured":"Kulic L, Alcaraz F, Klein G, Hofmann C, Yilmaz S, Abrantes JA, et al. Latest interim results from the Brainshuttle AD study, a phase 1b\/2a study of trontinemab in people with Alzheimer\u2019s disease. Clinical Trials on Alzheimer\u2019s Disease (CTAD) conference. 2024:LB01."}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-025-00737-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:20:13Z","timestamp":1764253213000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-025-00737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1186\/s12987-025-00737-7","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were performed in accordance with the European Communities Council Directive no. 86\/609, the directives of the Danish National Committee on Animal Research Ethics, and Danish legislation on experimental animals (license no. 2014-15-0201-00339).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The online version contains supplementary video material (\n                      \n                      ).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"H.H.H., E.A., J.L.S., M.R.M., C.G.S. and J.H.S. are employed by Gubra. H.H.H., M.R.M., C.G.S. and J.H.S. are shareholders in Gubra. S.T.S., F.W, M.S.K, A.J. and S.V. are employed by Lundbeck. A.J. is shareholder in Lundbeck.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}